ESMO World Congress on Gastrointestinal Cancer 2017

Oncology Meeting Resources

28 Jun - 01 Jul 2017, Barcelona, Spain

ESMO World GI 2017 square image

The ESMO World Congress on Gastrointestinal Cancer 2017 (World GI) is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts are open access. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Watch the ESMO scientific videos

Best Abstracts Session on Colorectal Cancer, Speaker: Filippo Pietrantonio

Tips for Practice: MSI Testing in GI Cancers, Speaker: Fatima Carneiro

Prevention of Colorectal Cancer, Speaker: Nadir Arber

The Role of Microbiome in Cancer Medicine, Speaker: James Godaert

All interviews from the event on the ESMO Channel





Format available

http://oncologypro.esmo.org/Meeting-Resourc...rker-for-response-to-anti-VEGFR-2-inhibition

Ramucirumab is a fully human monoclonal IgG1 antibody that specifically targets vascular endothelial growth factor receptor 2 (VEGFR-2). In the phase 3, randomized REACH study in patients with advanced...

Date: 28 Jun 2017
Presenter: Linda Lee
Resources: Abstract
Topics: Gastrointestinal Cancers, Translational Research, Biomarkers

http://oncologypro.esmo.org/Meeting-Resourc...n-and-liver-cancer-morbidity-rates-in-Poland

Liver cancer occurs in approximately 1% of Poles affected by all cancers. In 2014 its standardised incidence rates amounted to 2.9/100 thousand for males and 1.3/100 thousand for females.

Date: 28 Jun 2017
Presenter: Ewa Rychlik
Resources: Abstract
Topics: Gastrointestinal Cancers, Hepatobiliary Cancers

http://oncologypro.esmo.org/Meeting-Resourc...pectively-when-combined-with-cytotoxic-drugs

CNP exerts a catalase activity that differs between tumour and normal cells.rnThey have been reported to enhance the antitumor activity of doxorubicin, probably related to reactive oxygen species (ROS)...

Date: 28 Jun 2017
Presenter: Jose Vazquez Villa
Resources: Abstract
Topics: Gastrointestinal Cancers, Basic Science

http://oncologypro.esmo.org/Meeting-Resourc...s-of-gallbladder-Cancer-A-report-of-53-cases

Prognostic factors in gallbladder cancer remain an object of continuous discussion.rnThe aim of this study is to identify prognostic factors influencing survival for gallbladder cancer in the light of data reported in literature.

Date: 28 Jun 2017
Presenter: Mariem Benhami
Resources: Abstract
Topics: Gastrointestinal Cancers, Hepatobiliary Cancers

http://oncologypro.esmo.org/Meeting-Resourc...t-and-Memorial-Sloan-Kettering-Cancer-Center

Biomedical research is fundamental for unveiling pathologies of diseases and developing more effective means for treatment and prevention. Lack of resources and data is a factor hindering biomedical...

Date: 28 Jun 2017
Presenter: mariam kanso
Resources: Abstract
Topic: Gastrointestinal Cancers

http://oncologypro.esmo.org/Meeting-Resourc...P-in-relation-to-pH-physiological-vs-tumoral

CNP have received much attention because of their excellent catalytic activities, which are derived from the oxidation state switching between Ce4+ and Ce3+. The antioxidant state is dependent of the...

Date: 28 Jun 2017
Presenter: Jose Vazquez Villa
Resources: Abstract
Topics: Gastrointestinal Cancers, Basic Science

http://oncologypro.esmo.org/Meeting-Resourc...s-of-vitamin-E-in-cisplatin-induced-toxicity

Cisplatin is one of highly consumed and effective antitumor agents while its clinical application is accompanied by nephrotoxicity adverse reactions. Also other complication such as ototoxicity and hepatotoxicity are matter of concern.

Date: 28 Jun 2017
Presenter: Bahareh Hakiminia
Resources: Abstract
Topics: Gastrointestinal Cancers, Palliative and Supportive Care, Complications of Treatment

http://oncologypro.esmo.org/Meeting-Resourc...s-from-colorectal-cancer-A-multicenter-study

Surgical treatment of hepatic or pulmonary metastasis is the optimal therapeutic goal in metastatic colorectal cancer. We aim to analyze prognostic factors and outcome differences between resected liver limited vs lung limited metastases.

Date: 28 Jun 2017
Presenter: Haifa Rachdi
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...ancer-2017/Epidemiology-of-pancreatic-cancer

With a dramatic increase of incidence and a very poor prognosis, the treatment of pancreatic cancer remains a challenge. Unfortunately, the majority of cases are diagnosed at an advanced stage, where...

Date: 28 Jun 2017
Presenter: Nacera Caid
Resources: Abstract
Topics: Gastrointestinal Cancers, Pancreatic Cancer

http://oncologypro.esmo.org/Meeting-Resourc...ncer-via-modulation-of-CXCR2-and-av-integrin

Peritoneal carcinosis (PC) is the third common site of metastatic colorectal cancer which characterized by a very low survival rate. Surgical trauma has been identified as an important factor in the...

Date: 28 Jun 2017
Presenter: Mattias lepsenyi
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer